The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Chan Discusses Cabozantinib for the Treatment of NETs

Jennifer Chan MD, MPH
Published Online:2:55 PM, Wed November 1, 2017

Jennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.